LR-90 is an advanced glycation end product (AGE) inhibitor, inhibits inflammatory responses in human monocytes. LR-90 is also used in the research of diabetic animal model.

LRE1 is a specific and allosteric inhibitor of soluble adenylyl cyclase.

LRRK2 inhibitor 18(Compound 18) is a potent azaindazole leucine-rich repeat kinase 2 (LRRK2) inhibitor with Ki of 4.1 nM.

LRRK2-IN-1 inhibits both wild-type and G2019S mutant LRRK2 kinase activity with IC50 values of 13 nM and 6 nM , respectively with 0.1 mM ATP in the assay.

LSD1 inhibitor 24 is a novel potent, selective lysine-specific demethylase 1 (LSD1) inhibitor with IC50 of 1 nM, induces CD11b expression in THP-1 cells with EC50 of 8 nM.

LSD1 inhibitor-1 is a bisguanidine polyamine analogue that exhibits noncompetitive and specific LSD1 inhibition, with 14.1% remaining LSD1 activity at 10 uM in vitro.

ORY-1001 dihydrochloride (RG-6016, Ladademstat) is a highly potent, selective inhibitor of lysine-specific demethylase KDM1A (LSD1) with IC50 of 18 nM, displays high selectivity for KDM1A over other FAD-containing monoamine oxidases.

LSD1-IN-11p is a reversible LSD1 inhibitor with IC50/Kd of 79/21 nM.

LSD1-IN-32 is a potent, reversible lysine specific demethylase 1 (LSD1) inhibitor with biochemical IC50 of 83 nM, Kd of 32 nM, cell EC50 of 0.67 uM.

L-SelenoMethionine is a major natural food-form of selenium.

LSN 3213128 is a novel potent, selective and orally-bioavailable antifolate with potent and specific inhibitory activity for AICARFT.

LSN2814617 is a neurotoxic positive allosteric modulator.

LSN3154567 is a novel inhibitor of NAMPT with IC50 of 18 nM (NCI-H1155 cell), 49 nM (Calu-6 cell), 333 nM (HCC1937 cell), and 389 nM (MCF-7 cell), respectively.

LSP1-2111 is a potent, selective, and brain penetrant group III mGluRs agonist with EC50 of 2.2 and 1.7 uM for mGluR4 and mGluR6, respectively.

LSP4–2022 is a novel potent, selective, brain-penetrant mGluR4 agonist with EC50 of 0.11 uM in cell-based assays.

LSZ102 is a potent, orally bioavailable Selective Estrogen Receptor Degrader (SERD) for the Treatment of Estrogen Receptor Positive Breast Cancer.

L-Thyroxine

LTI-291 is a Glucocerebrosidase (Gcase) activator for the treament of Parkinson's disease (PD).

LTURM34 is a specific DNA-PK inhibitor with an IC50 of 0.034 μM.

LTV-1 is a highly potent, cell-permeable and reversible LYP (lymphoid tyrosine phosphatase) inhibitor with IC50 of 508 nM.

This product is discontinued. LTX-315 (Oncopore) is a synthetic 9-mer anticancer peptide that preferentially permeabilizes mitochondrial membranes, thereby causing partially BAX/BAK1-regulated, caspase-independent necrosis.

The product is discontinued. LTX-401 (LTX401) is an oncolytic amino acid derivative with potential immunogenic properties, selectively destroys the structure of the Golgi apparatus.

Lu AE58054 is an in-vitro potency and selectivity, in-vivo binding affinity and effect of the 5-HT(6)R antagonist with a Ki value of 0.83 nM.

Lu AF21934 is a brain-penetrating positive allosteric modulator of the metabotropic glutamate receptor 4 (mGlu4),reduces the harmaline-induced hyperactivity

Lubiprostone(SPI-0211;RU0211) is a gastrointestinal agent used for the treatment of idiopathic chronic constipation.

Lucidin (NSC 30546) is a natural component of Rubia tinctorum L. lucidin is mutagenic in bacteria and mammalian cells.

LUF6000 is a potent, selective, positive allosteric modulator (enhancer) of human A3 adenosine receptor, enhance Emax but without affecting agonist potency.

LUF7346 is a novel hERG allosteric modulator that slows IKr deactivation and positively shifting IKr inactivation.

Luliconazole(NND 502) is an azole antifungal indicated for the topical treatment of interdigital tinea pedis.

Lumateperone (ITI-007) is a potent 5-HT2A antagonist (Ki=0.54 nM), postsynaptic D2 antagonist(Ki=32 nM), and SERT blocker (Ki= 61 nM).

Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a SERT blocker (Ki = 61 nM).

Lupus erythematosus suppressant as well as an antimalerial and antirheumatic.

Lurasidone is an atypical antipsychotic, inhibits Dopamine D2, 5-HT2A, 5-HT7, 5-HT1A and noradrenaline α2C with IC50 of 1.68 nM, 2.03 nM, 0.495 nM, 6.75 nM and 10.8 nM, respectively.

Lurasidone is a novel psychotropic agent that has been shown in studies of cloned human receptors to be an antagonist at the 5-HT2A receptor.

Lusutrombopag（S-888711） is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.

LUT014 is a novel BRAF agonist.

Luteolin 7-O-glucuronide could inhibit Matrix Metalloproteinases (MMP) activities, with IC50s of 17.63, 7.99, 11.42, 12.85, 0.03 μM for MMP-1, MMP-3, MMP-8, MMP-9, MMP-13, respectively.

Luteolin-3-O-beta-D-glucuronide is a luteolin glucosiduronic acid consisting of luteolin having a beta-D-glucosiduronic acid residue attached at the 3'-position.

Luteolin-7-rutinoside has both anti-arthritic and antifungal activities, can result in a combination therapy for the treatment of fungal arthritis due to C. albicans infection.

LV-320 (LV320) is a novel potent, cell-active, allosteric inhibitor of the autophagy-related cysteine protease ATG4B with IC50 of 24.5 uM in ATG4B cleavage assays.

LX-1031 is a potent, orally active tryptophan 5-hydroxylase (TPH) inhibitor with potency of 10-100 nM, reduces 5-HT synthesis peripherally.

LX1606 is an orally bioavailable, small-molecule, tryptophan hydroxylase (TPH) inhibitor with potential antiserotonergic activity.

LX-2343 is a novel non-ATP competitive PI3K inhibitor, negatively regulating AKT/mTOR signaling, thus promoting autophagy, and increasing A-beta clearance.

LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.

LX-2931 (LX2931) is a potent, selective and orally bioavailable S1P lyase (S1PL) inhibitor.

LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.

LX7101 is a potent, dual LIMK and ROCK inhibitor with IC50 of 4.3/32//69/32/ nM for LIMK2/LIMK1/ROCK1/ROCK2, respectively.

LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor.

LXR-623 is a novel Liver X Receptor modulator

LXS196 is a potent, selective and orally active protein kinase C (PKC) inhibitor, with IC50 values of 1.9 nM, 0.4 nM and 3.1 μM for PKCα, PKCθ and GSK3β, respectively. It can be used for the treatment of uveal melanoma.

LY 2318912 is a potent, competitive, small molecule inhibitor of anandamide uptake with IC50 of 7.27 nM, shows high affinity against anandamide transporter binding site with Kd o f7.62 nM.

LY 311727 is a specific group II sPLA2 (phospholipase A2 (PLA2)) inhibitor which has been reported to attenuate VEGF-mediated platelet-activating factor (PAF) synthesis in HUVEC and BAEC cells.

LY 392098 is a selective, potent and centrally active positive allosteric modulator of AMPAR.

LY2090314 is a potent inhibitor of glycogen synthase kinase-3 (GSK-3) with IC50s of 1.5 nM and 0.9 nM for GSK-3α and GSK-3β respectively.

LY2109761 is a novel selective TGF-β receptor type I/II (TβRI/II) dual inhibitor with Ki of 38 nM and 300 nM, respectively; shown to negatively affect the phosphorylation of Smad2.

LY2119620 is a specific, and allosteric agonist of human M2 and M4 muscarinic acetylcholine receptors.

LY2157299 is a potent TGFβ receptor I (TβRI) inhibitor with IC50 of 56 nM. Phase 2.

LY2183240 is a novel and highly potent blocker of anandamide uptake (IC50 = 270 pM).

LY2228820 is a novel and potent p38MAPK inhibitor (the IC50 for p38αMAPK and p38βMAPK were 7 nM and 3 nM, respectively).

LY223982 is a potent and specific inhibitor of leukotriene B4 receptor, with an IC50 of 13.2 nM against [3H]LTB4 binding to LTB4 receptor.

LY2334737 is an orally available prodrug of gemcitabine which is a nucleoside analog used as chemotherapy.

LY2365109 is a potent and selective GlyT1 inhibitors with IC50 value of 15.8 nM.

LY2409881 is a novel inhibitor of IκB kinase β (IKK2).

LY2452473 is an orally bioavailable, selective androgen receptor modulator (SARM).

LY2510924 is an inhibitor of CXC chemokine receptor 4 (CXCR4), with potential antineoplastic activity.

LY2584702 is a potent, selective, ATP-competitive inhibitor of P70 S6 kinase-1 (p70S6K1) with IC50 of 4 nM.

LY2584702 is a potent, selective, ATP-competitive inhibitor of P70S6 kinase-1 (p70S6K1) with IC50 of 4 nM.

LY-2584702 is an orally available inhibitor of p70S6K signaling; inhibits p70S6K and prevents phosphorylation of the S6 subunit of ribosomes.

LY2603618(IC-83) is a potent and selective small molecule inhibitor of Chk1 protein kinase activity in vitro (IC50=7 nM) and the first selective Chk1 inhibitor to enter clinical cancer trials.

LY2606368 2Hcl is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase.

LY2606368 is a potent and selective ATP competitive inhibitor(IC50=1.5 nM in SW1990 cell) of the Chk1 protein kinase.

LY2608204 is a activator of glucokinase (GK) with EC50 of 42 nM.

LY2623091 (LY-2623091) is an orally administered mineralocorticoid receptor antagonist for the treatment of essential hypertension and chronic kidney disease..

LY2624803 is a novel potent histamine H1 and 5HT-2A receptor modulator in the pipeline for treating insomnia..

LY2784544 is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. Phase 2.

LY2794193 is a highly potent and selective mGlu3 receptor agonist with Ki of 0.93 nM and EC50 of 47 nM, >100-fold selectivity over mGlu2 receptor..

LY2795050 is a novel selective κ-opioid Receptor (KOR) antagonist (IC50=0.72 nM) and has the potential as a PET tracer to image KOR in vivo.

LY2801653 2HCl is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).

LY2801653 is a potent, orally bioavailable, small-molecule inhibitor of c-MET kinase(Ki= 2 nM).

LY2811376 is the first orally available non-peptidicβ-secretase(BACE1) inhibitor with IC50 of 239 nM-249 nM.

LY2828360 is a slowly acting but efficacious G protein-biased cannabinoid (CB2) agonist, inhibiting cAMP accumulation and activating ERK1/2 signaling.

LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2835219 is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.

LY2857785 is a potenrt, reversible and ATP-competitive CDK9 inhibitor with IC50 of 11 nM, also inhibits CDK8 (IC50=16 nM) and weakly inhibits CSK7 (IC50=246 nM).

LY2874455 is a novel and potent FGF/FGFR inhibitor.

LY2886721 is an BACE inhibitor used for the treatment of Alzheimer's Disease.

LY2922470 (LY-2922470) is a potent, selective, orally available GPR40 agonist with EC50 of 7 nM.

LY294002 is a PI3K inhibitor for p110α, p110δ and p110β with IC50 of 0.5 μM, 0.57 μM and 0.97 μM, respectively.

LY2940094 is a potent and selective nociceptin receptor antagonist which inhibits excessive feeding behavior in rodents.

LY2940680 binds to the Smoothened (Smo) receptor and potently inhibits Hedgehog (Hh) signaling.

LY2955303 is a potent and selective RAR-gamma antagonist for the treatment of osteoarthritis pain.

LY2979165 (MP-101) is the alanine prodrug of LY2812223, a selective orthosteric mGlu2 receptor agonist.

LY 3000328 is a potent and selective Cathepsin S (Cat S) inhibitor with IC50s of 7.7 and 1.67 nM for hCat S and mCat S, respectively.

LY3009120 is a potent and selective pan-RAF inhibitor with potential anticancer activity.

LY3023414 is an oral ATP competitive inhibitor of the class I PI3K isoforms, mTOR and DNA-PK.

LY303511, an inactive analogue of LY294002, is a mTOR inhibitor that did not inhibit PI3-K.

LY3039478 a orally bioavailable, novel small molecule Notch inhibitor with an IC50 of ~1nM in most of the tumor cell lines tested.

LY305 (LY-305) is a non-steroidal selective androgen receptor modulator (SARM) with Ki of 2.03 nM, demonstrates potent agonist activity in the aforementioned C2C12 cellular assay (EC50=0.499 nM).

LY310762 is a 5-HT1D receptor antagonist with Ki of 249 nM, having a weaker affinity for 5-HT1B receptor.

LY3130481 (CERC611) is a potent, selective, noncompetitive TARP γ8-associated AMPA receptors with IC50 of 65.3 nM (GluA1/TARP γ-8), with no activity for γ-2 (cerebellum) or other TARP members.

LY3143921 (LY-3143921) is an orally available, potent, selective inhibitor of Cdc7 kinase inhibitor, inhibits CDC7/DBF4 I and pMCM2 (S53) with IC50 values of 3.3 nM and 290 nM, respectively..

LY3154207 is a potent and selective dopamine receptor D1 positive allosteric modulator for the treatment of Parkinson's disease dementia.

LY315920 (Varespladib) is a potent and selective human non-pancreatic secretory phospholipase A2 (hnsPLA) inhibitor with IC50 of 7 nM,. Phase 3.

LY3177833 is a novel CDC7 inhibitor,CDC7/DBF4 IC50 = 3.3 nM, pMCM2 (S53) IC50 = 290 nM and IVTI TEC70 = 1.6 mcM.

LY3200882 is a novel, highly selective TGFβRI small molecule inhibitor.

LY320135 is a selective cannabinoid (CB) receptor 1 antagonist (Kis = 224 and >10,000 nM for CB1 and CB2, respectively, in vitro).

LY3202626 is a small molecule non-selective BACE1 inhibitor, causes dose-dependent reductions in CSF and plasma Aβ concentrations, shows potential for the treatment of Alzheimer's disease..

LY3214996 is a selective and novel ERK1/2 inhibitor with IC50 of 5 nM for both enzymes in biochemical assays. It potently inhibits cellular phospho-RSK1 in BRAF and RAS mutant cancer cell lines.

LY3295668 is a potent, orally active and highly specific Aurora-A kinase inhibitor, with Ki values of 0.8 nM and 1038 nM for AurA and AurB, respectively.

LY-333,531 Hydrochloride is a potent, selective inhibitor of Protein Kinase C isozymes, PKC beta I (IC50 = 4.7 nM) and PKC beta II (IC50 = 5.9 nM). It is potentially beneficial for cancer research.

LY334370 is a selective 5-HT1F receptor agonist with a Ki of 1.6 nM.

LY335979 (Zosuquidar) is a potent modulator of P-glycoprotein-mediated multidrug resistance with Ki of 60 nM.

LY344864 is a selective receptor agonist with an affinity of 6 nM (Ki) at the recently cloned 5-HT1F receptor.

LY-345899 (LY345899) is a novel potent, cytoplasmic and mitochondrial methylenetetrahydrofolate dehydrogenase MTHFD1 and MTHFD2 inhibitor with IC50 of 96 nM and 663 nM, respectively; MTHFD2 is a novel target for drug development.

LY354740 is an agonist of the group II metabotropic glutamate receptor (mGluR) subtypes mGluR2 and mGluR3 (Kis = 99 and 94 nM, respectively).

LY364947 is a potent ATP-competitive inhibitor of TGFβR-I with IC50 of 59 nM, shows 7-fold selectivity over TGFβR-II.

LY379196 is a highly specific PKCβ inhibitor with IC50 of 30-50 nM for PKCβI and PKCβII, displays >10-fold selectivity of PKCα, δ, η, and γ (>600 nM).

LY404039 is an inhibitor for mGluR1(Ki=149 nM) and mGluR2(Ki= 92 nM), which can also inhibit dopamine receptor.

LY-404187 is a potent, selective, positive allosteric modulator of AMPA receptor (AMPAR) with EC50 of 1.3 uM.

LY411575 is a potent γ-secretase inhibitor with IC50 of 0.078 nM/0.082 nM (membrane/cell-based), also inhibits Notch clevage with withIC50 of 0.39 nM.

LY-487379 is a potent, selective positive allosteric modulator of mGluR2 (EC50=0.27 uM) without activity at mGluR3; shows no intrinsic agonist or antagonist activity at hmGluR2, markedly potentiates glutamate-stimulated [35S]GTPgammaS binding at hmGluR2; potentiates synaptically evoked mGluR2 responses in rat hippocampal slices, modulates excitatory synaptic transmission in the rat globus pallidus.

LY-487379 is a potent, selective positive allosteric modulator of mGluR2 (EC50=0.27 uM) without activity at mGluR3.

LY500307 is a potent, selective estrogen receptor β agonist with EC50 of 0.66 nM, 32-fold selectivity against estrogen receptor α. Phase 2.

LY-503430 is a novel AMPA receptor (AMPAR) potentiator that selectively enhances glutamate-induced calcium influx into HEK293 cells transfected with human GLUA1, GLUA2, GLUA3, or GLUA4 AMPA receptors with EC50 of 0.1-4 uM.

LY-83583 is an inhibitor of soluble guanylate cyclase (sGC) and of cGMP production, inhibits sGC in human platelets with IC50 of 2 uM.

LY900009 (LY-900009) is an orally active small molecule inhibitor of Notch signalling via selective inhibition of the γ-secretase protein.

Lycobetaine（Ungeremine） is a potential biofungicide against Penicillium roqueforti and Aspergillus niger.

LYN-1604 is a potential ULK1 agonist with IC50 of 1.66 μM against MDA-MB-231 cells and it binds to wild-type ULK1 with a binding affinity in the nanomole range (Kd=291.4 nM).

Lyn-IN-1 is a potent and selective dual Bcr-Abl/Lyn inhibitor..

LYPLAL1-IN-11 is a potent, selective, covalent inhibitor of lysophospholipase-like 1 (LYPLAL1) with IC50 of 6 nM.

Lys01 trihydrochloride (Lys05) is a novel lysosomal autophagy inhibitor with IC50 values of 3.6, 3.8, 6 and 7.9 μM for 1205Lu, c8161, LN229 and HT-29 cell line in the MTT assay.

Lys05 is a new lysosomal autophagy inhibitor which potently accumulates within and deacidifies the lysosome of both cells and tumors, resulting in sustained inhibition of autophagy and tumor growth.

LYS228 is a novel potent monobactam that shows potent activity against carbapenem-resistant isolates of Enterobacteriaceae with MIC90 of 2 ug/ml.

Vafidemstat (ORY-2001) is an oral, brain penetrant drug that inhibits LSD1 and MAOB by reducing cognitive impairment, including memory loss and neuroinflammation. It also has neuroprotective effects.

LysoPC(14:0/0:0) is a lysophospholipid (LyP). It is a monoglycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site.

L-α-Hydroxyglutaric acid disodium salt (L-2-Hydroxyglutarate.

M 344 enhances the sensitivity of human squamous carcinoma cells to radiation and promotes cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells (ED50 = 2.3 μM).

M-110 is a potent, selective inhibitor of PIM kinase family with preference for PIM-3 with IC50 of 0.047, 2.5 and 2.5 uM for PIM3, PIM1 and PIM2, respectively.

M2698 is a potent dual-inhibitor of p70S6K and Akt that affects tumor growth in mouse models of cancer and crosses the blood-brain barrier.

M4284 (M-4284) is a high-affinity biphenyl mannoside FimH inhibitor with HAI of 16 nM in hemagglutination assay.

M-525 is a first-in-class, highly potent, irreversible small-molecule inhibitor of the menin-MLL interaction with binding IC50 of 3.3 nM in FP assays.

MA-0204 is a potent, selective PPARδ modulator with good pharmacokinetic properties.

MAC1 (Monastrol Antagonizing Compound 1) is a small molecule that can rescue spindle bipolarity in cells lacking Eg5 activity.

MAC13772 is a potent inhibitor of BioA with an IC50 of 250 nM, a novel antibacterial inhibitor that selectively inhibits PABA biosynthesis in M tuberculosis..

MAC168425 is a novel antibacterial inhibitor that interferes with glycine metabolism in E coli..

MAC173979 is a novel time-dependent inhibitor of p-aminobenzoic acid biosynthesis with IC50 of 30 uM, represents the first PABA biosynthesis inhibitor with activity against Gram-negative bacteria..

mAChR-IN-1 is a potent muscarinic cholinergic receptor(mAChR) antagonist with IC50 of 17 nM..

macitentan (Actelion-1, ACT-064992) is an orally active, non-peptide dual endothelin (ET)A/B receptor antagonist with IC50 of 0.5 nM/391 nM.

Macranthoidin B is a major bioactive saponin in rat plasma after oral administration of extraction of saponins from Flos Lonicerae.

Mad2 Inhibitor-1 (M2I-1) is a small molecule protein-protein interaction inhibitor targeting the mitotic spindle assembly checkpoint.

Madrasin inhibits pre-mRNA splicing in vitro and modify splicing of endogenous pre-mRNA.

Magnesium ionophore III is an onophore used in solvent polymeric membrane electrodes for the assay of Mg2+ activities in blood serum in vitro.

MAI-150 is a peptidomimetic inhibitor of APC-Asef interaction, blocks colorectal cancer migration..

MAI-400 (MAI400) is a novel peptide inhibitor of APC-Asef interaction with Kd of 12 nM and IC50 of 0.25 uM.

MAK683 is a novel PRC2/EED inhibitor.

MAL3-101 is a Hsc70 modulator that inhibits Hsp70 ATPase activity, exhibits antiproliferative activity in breast cancer cells SK-BR-3 with IC50 of 27 uM.

MALAT1 inhibitor 5 (Malat1 inhibitor 5) is a selective small molecule targeting of Metastasis-associated lung adenocarcinoma transcript 1 (Malat1/MALAT1 mouse/human), a highly conserved long non-coding RNA; does not affect Neat1 lncRNA levels.

Malic Enzyme inhibitor ME1 (ME1) is a small molecule inhibitor of Malic Enzyme (ME1) with IC50 of 0.15 uM, suppresses growth of human CRC cells in vitro, with little effect on normal rat intestinal epithelial cells..

Malotilate

MALT1 paracaspase inhibitor 3 is a potent, specific, covalent inhibitor of MALT1 paracaspase with Ki of 10 nM, exhibits 10-and 100-fold improved potency in vitro and in vivo compared with Z-VRPR-fmk.

Maltitol is a sugar alcohol used as a sugar substitute. It has 75-90% of the sweetness of sucrose (table sugar) and nearly identical properties. Maltitol may also be used as a plasticizer in gelatin capsules, as an emollient, and as a humectant.

Maltohexaose is a natural saccharide, and can be produced from amylose, amylopectin and whole starch.

Maltopentaose is the shortest chain oligosaccharide that can be classified as maltodextrin and is also used in a study to investigate glycation and phosphorylation of α-lactalbumin.

Manidipine 2Hcl (CV-4093) is a dihydropyridine compound and a calcium channel blocker for Ca2+ current with IC50 of 2.6 nM.

Manidipine is a dihydropyridine L- and T-type calcium channel blocker.

MAP4K4-IN-17 is a potent and highly selective MAP4K4 inhibitor with IC50 of 14.9 nM, showes improved overall drug-like properties compared to PF-06260933.

MAP4K4-IN-37 is a potent, selective, orally active inhibitor of serine-threonine kinase MAP4K4 with IC50 of 0.4 nM.

MAP4K4-IN-44 is a potent, moderately selective small molecule MAP4K4 inhibitor with IC50 of 5 nM in LC3K assay, demonstrates favorable in vivo bioavailability in mouse..

Mapracorat (ZK 245186) is a potent, selective and non-steroid glucocorticoid receptor (GR) agonist with binding Ki of 1.9 nM.

Maraviroc (Selzentry, UK-427857, Celsentri) is a CCR5 antagonist for MIP-1α, MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM, respectively.

Marbostat-100 is a potent, selective HDAC6 inhibitor with Ki of 0.7 nM, displays >200-fold selectivity over HDAC1-5, and HDAC7-10.

Maribavir(GW257406X; BW1263W94; 1263W94) inhibits HCMV replication is by inhibition of an HCMV encoded protein kinase enzyme called UL97 or pUL97.

Marimastat is a broad spectrum MMP inhibitor and selective TACE inhibitor

Marinopyrrole A (Maritoclax) is a selective Mcl-1 antagonist. It binds to Mcl-1, but not Bcl-XL, and targets Mcl-1 for proteasomal degradation. Maritoclax disrupts the interaction between Bim and Mcl-1 with an IC50 of 10.1 μM.

Marmesin is a coumarin originally isolated from the mature bark of A. marmelos.

Maropitant citrate (Cerenia) is a selective neurokinin 1 receptor (NK1) antagonist for prevention of vomiting due to motion sickness in dogs..

Maropitant is a neurokinin (NK1) receptor antagonist.

MARPIN is a novel ATR-Chk1 pathway inhibitor that inhibits hydroxyurea (HU)-induced phosphorylation of Ser345 on Chk1 with IC50 of 7.7 uM.

Masitinib is a broad coronavirus 3CL inhibitor that effectively blocks replication of SARS-CoV-2. Science 20 Jul 2021: eabg5827 DOI: 10.1126/science.abg5827

Mavacamten（MYK-461）is a small molecule that reduces contractility by decreasing the ATPase activity of the cardiac myosin heavy chain.

Mavatrep is an orally bioavailable TRPV1 antagonist (Ki=6.5 nM), exhibits minimal effect on the enzymatic activity (IC50 > 25 μM) of CYP isoforms 3A4, 1A2, and 2D6.

Mavoglurant (AFQ056) is an experimental drug candidate for the treatment of fragile X syndrome.It exerts its effect as an antagonist of the metabotropic glutamate receptor 5 (mGLU5).

MAZ51 is an indolinone that selectively antagonizes the activation of VEGFR3 by VEGFC (IC50 = 1 µM) without blocking VEGFC-mediated stimulation of VEGFR2.

MB-07811 (VK-2809) is an orally bioavailable, liver-targeted prodrug of MB07344, which is a thyroid hormone receptor-beta agonist (TRβ) agonist, efficiently converted to MB07344 by liver microsomes in vivo.

MB710 is a small-molecule p53 mutant Y220C stabilizer, binds tightly to the Y220C pocket and stabilizes p53-Y220C in vitro..

MB725 is a small-molecule p53 mutant Y220C stabilizer, induces selective viability reduction in several p53-Y220C cancer cell lines (Huh7 cell IC50=10 uM).

MBP146-78 inhibits the growth of Eimeria spp. both in vitro and in vivo.

MBQ-167 is a dual Rac/Cdc42 inhibitor, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.

MBX-2982 is a selective, orally-available GPR119 agonist for the treatment of type 2 tiabetes.

MBX-4132 a trans translation inhibitor by binding to the bacterial ribosome.

MC1568 is a class II (IIa) HDAC inhibitor selective for HDAC4 and HDAC6

MC-1575 is a potent and selective class IIa HDAC inhibitor with IC50 of 440 nM for maize HD1-A, displays >70-fold selectivity over HD1-B.

MC180295 (MC-180295, MC 180295) is a novel potent, highly selective CDK9 inhibitor with IC50 of 5 nM, displays >22-fold selectivity over other CDKs.

MC2884 is a novel hybrid, dual HAT/EZH2 inhibitor with IC50 of 3.27, 8.35 and 4.56 uM for CBP, KAT5 and p300, respectively.

MC3343 (MC-3343) is a novel potent, non-nucleoside DNA methyltransferase (DNMT) inhibitor with IC50 of 5.7 and 1.7 uM for DNMT1 and DNMT3a.

Mca-DEVDAPK(Dnp)-OH is a substrate for caspase-3.

Mca-PL is a fluorogenic peptide that has been used as a building block in the synthesis of Mca-PLGL-Dpa-AR-NH2, a fluorogenic substrate for matrix metalloproteinase-2 (MMP-2) and MMP-7.

MCB-613 is a novel and potent stimulator of p160 steroid receptor coactivators (SRCs). It is a Pan-SRCs stimulator.

Netoglitazone, also known as isaglitazone and MCC-555, is an agent belonging to the glitazone class of antidiabetic agents with antihyperglycemic activity. Netoglitazone exerts both peroxisome proliferator-activated receptor (PPAR) alpha and gamma agonist activity. Netoglitazone decreases bone formation and increases marrow adipocyte formation in vivo.MCC 555 (Isaglitazone.

MCL0129 is a selective, potent melanocortin-4 receptor (MC4R) antagonist with Ki of 7.9 nM, without affinity for MC1 and MC3.